Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEGIN: Infliximab in Intestinal Behcet's Disease
NCT02505568Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab in Behcet's disease (BD), sponsored by Janssen Pharmaceutical. Primary endpoint: Mean Decrease in Disease Activity Index for Intestinal Behcet's Disease (DAIBD) Score of 20 or More From Baseline at Week 8. Started Jul 2015; status: completed.
02
Drugs
infliximab
03
Conditions
Behcet's disease (BD)
Beyond the preview
Go deeper on NCT02505568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505568.